CEBPA

Across TCGA pan-cancer cohorts, CEBPA mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated CEBPA data layer compared with 25 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher CEBPA mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated CEBPA expression acts as an unfavorable survival marker, although some lineages such as LSCC and HNSC show a favorable association.

LSCC, HNSC, and LUAD are the cancer types where CEBPA mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	DFS	Quartile	II,III,IV	1.000	0.520	.005	15	view →
HNSC	DFS	Tertile	II,III,IV	0.807	0.507	.009	8	view →
LUAD	DFS	Quartile	II,III,IV	0.611	0.903	.024	7	view →
GBM	OS	Median	All	0.598	0.395	.020	2	view →
CCRCC	OS	Tertile	All	0.918	0.682	.036	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

CEBPA–LSCC (DFS)

Open the LSCC breakdown →